KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amneal Pharmaceuticals (AMRX) Common Equity (2017 - 2025)

Amneal Pharmaceuticals (AMRX) has 9 years of Common Equity data on record, last reported at -$71.3 million in Q4 2025.

  • For Q4 2025, Common Equity rose 34.72% year-over-year to -$71.3 million; the TTM value through Dec 2025 reached -$71.3 million, up 34.72%, while the annual FY2025 figure was -$71.3 million, 34.72% up from the prior year.
  • Common Equity reached -$71.3 million in Q4 2025 per AMRX's latest filing, up from -$110.0 million in the prior quarter.
  • Across five years, Common Equity topped out at $407.4 million in Q1 2022 and bottomed at -$132.0 million in Q1 2025.
  • Average Common Equity over 5 years is $108.8 million, with a median of $142.7 million recorded in 2023.
  • Peak YoY movement for Common Equity: crashed 646.03% in 2024, then soared 34.72% in 2025.
  • A 5-year view of Common Equity shows it stood at $367.0 million in 2021, then tumbled by 49.87% to $184.0 million in 2022, then plummeted by 89.12% to $20.0 million in 2023, then plummeted by 646.03% to -$109.3 million in 2024, then skyrocketed by 34.72% to -$71.3 million in 2025.
  • Per Business Quant database, its latest 3 readings for Common Equity were -$71.3 million in Q4 2025, -$110.0 million in Q3 2025, and -$112.5 million in Q2 2025.